Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%

MT Newswires Live

Mar 19

Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.

The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.

IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.

Its shares jumped 5% in recent trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2620292812"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620292812\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620292812?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620292812","market":"sg","top_or_hot":-1,"title":"Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%","media":"MT Newswires Live","content":"<html><body><p> Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.</p><p>The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.</p><p>IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.</p><p>Its shares jumped 5% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Completes Single Ascending Dose Portion of Phase One Autoimmune Disease Therapy Candidate Study; Shares Rise 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-19 09:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.</p><p>The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.</p><p>IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.</p><p>Its shares jumped 5% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620292812","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620292812","pubTimestamp":1773883807,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immutep  completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.Its shares jumped 5% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","IMM.AU":"IMMUTEP LTD"},"translate_title":"Immutep完成一期自身免疫性疾病候选疗法研究的单次递增剂量部分；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":1},"content_text":"Immutep (ASX:IMM) completed the single ascending dose portion of its first-in-human phase one study evaluating its IMP761 therapy candidate, with dosing up to 14 milligrams per kilogram, according to a Thursday Australian bourse filing.The therapy candidate was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed. The study is currently progressing in the multiple ascending dose portion, which is expected to be completed in the September quarter. This portion is evaluating the pharmacokinetics and safety of IMP761 across two dose levels.IMP761 is a LAG-3 agonist antibody that enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T-cell responses in autoimmune diseases.Its shares jumped 5% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}